New Blood Cancer Vaccine Reduces Death Risk By 41%

Notably, a new vaccine designed to treat an aggressive form of blood cancer has shown promising results in a major clinical trial, reducing the risk of death among certain leukemia patients by 41%.

HealthNews Info Wire3 min read
New Blood Cancer Vaccine Reduces Death Risk By 41%

Notably, a new vaccine designed to treat an aggressive form of blood cancer has shown promising results in a major clinical trial, reducing the risk of death among certain leukemia patients by 41%.

Article outline

  1. What happened
  2. Why it matters
  3. The key numbers
  4. The bottom line

Key points

  • Scientists Develop Magic Comb That Regrows Almost 100% of Hair in Just 28 Days.
  • Your Barber Might Be Passing You Hepatitis C and You'd Never Know It.
  • AML is an aggressive form of blood cancer that affects approximately 20, 000 individuals annually in the United States.
  • According to results confirmed, patients who received the vaccine survived for a median of 24 months, compared with 14.7 months for those receiving other available treatments.
  • The trial focused on patients whose leukemia had returned after previous treatment but who had achieved another remission and were ineligible for bone marrow transplants.

Notably, the vaccine, known as galinpepimut-S (GPS), was developed at Memorial Sloan Kettering Cancer Center and tested by Sellas Life Sciences in a Phase 3 clinical trial involving 126 patients with acute myeloid leukemia (AML).

AML is an aggressive form of blood cancer that affects approximately 20, 000 individuals annually in the United States. Although chemotherapy can bring the disease into remission, it frequently returns, making long-term treatment tough.

For context, the trial focused on patients whose leukemia had returned after previous treatment but who had achieved another remission and were ineligible for bone marrow transplants.

Unlike traditional vaccines applied to prevent diseases, GPS works by helping the immune system identify and attack leukemia cells that remain after chemotherapy, potentially reducing the risk of the cancer returning.

Meanwhile, the vaccine uses peptides. It are components of proteins, to stimulate an immune response against cancer cells. It can additionally be produced as a ready-made treatment without requiring a separate formulation for each patient.

Sellas documented that the vaccine was generally well tolerated, with reactions at the injection site being the most common side effect.

For context, the firm aims to release detailed trial findings at a future medical conference and seek approval from the US Food and Drug Administration (FDA), with an application projected in the first half of 2027. Stay Connected with ProPakistani. Obtain the latest international news and global stories wherever you prefer. Follow on Google Discover. Follow on Google News Join WhatsApp. See more ProPakistani stories in Google Search and Top Stories.

In short, new Blood Cancer Vaccine Reduces Death Risk By 41% is the central thread here, and readers can expect follow-up reporting as the picture becomes clearer.

Leave a Reply

Your email address will not be published. Required fields are marked *